Acura Pharma (ACUR), Pfizer (PFE) Confirm FDA Approval of Oxectatm for Pain Management
Tweet
Share
E-mailGet Alerts ACUR Hot Sheet
Join SI Premium – FREE
Acura Pharma (Nasdaq: ACUR), Pfizer (NYSE: PFE) confirm FDA marketing approval of Oxectatm for acute and chronic moderate to severe pain management.
OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This AVERSION® Technology is a unique composition of commonly used pharmaceutical ingredients. Pfizer is licensing the technology in OXECTA from Acura.
"We are excited to be partnered with Pfizer to bring OXECTA to patients who need opioids to manage their pain," said Robert Jones, interim president and CEO of Acura. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."
OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This AVERSION® Technology is a unique composition of commonly used pharmaceutical ingredients. Pfizer is licensing the technology in OXECTA from Acura.
"We are excited to be partnered with Pfizer to bring OXECTA to patients who need opioids to manage their pain," said Robert Jones, interim president and CEO of Acura. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synaptics CFO resigns amid pending ON Semiconductor merger
- Kaos Capital pushes for board changes at Capricor Therapeutics
- Getty Realty discloses separation terms for departing accounting officer
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
